|
KMID : 1034820220180040539
|
|
Molecular & Cellular Toxicology
2022 Volume.18 No. 4 p.539 ~ p.548
|
|
|
Normobaric hyperoxia re-sensitizes paclitaxel-resistant lung cancer cells
|
|
Im Jeong-Hyeon
Kwon Hee-Young
Kim In-Kyoung
Yeo Chang-Dong
Kim Sei-Won
Lee Hea-Yon
Kang Hye-Seon
Lee Sang-Haak
|
|
|
Abstract
|
|
|
Background: Chemoresistance is a substantial obstacle in cancer therapy. The microenvironment of solid tumor growth can be hypoxic, which promotes the survival, growth, and progression of cancer cells and reduces the effects of chemotherapy and radiotherapy. Hyperoxia treatment has potential to enhance cancer therapies.
Objective: We evaluated whether normobaric hyperoxia (NBO) therapy has an anticancer effect and can be a strategy for overcoming anticancer drug resistance. Human alveolar adenocarcinoma (A549) and paclitaxel (PTX)-resistant (A549/PR) cell lines were used. Cells were assessed after exposure to room air (RA) or NBO for 48 h with and without PTX application.
Results: NBO exposure inhibited cell viability, migration abilities, and proliferation in both cell lines. Chemo-resistant cell lines have shown variable viability upon NBO exposure. NBO exposure induced critical cytotoxicity and attenuated the characteristics of cancer in A549/PR cells. NBO induced a decline of chemoresistance in A549/PR cells when co-treated with PTX, consequently increasing cell death. In addition, NBO leads to intracellular reactive oxygen species and induced endoplasmic reticulum (ER) stress through the CCAAT/enhancer-binding protein homologous protein (CHOP) signaling pathway.
Conclusion: In summary, NBO increased cell death in lung cancer cells and promoted PTX re-sensitization in A549/PR cells through apoptosis and CHOP-mediated ER stress.
|
|
|
KEYWORD
|
|
|
Lung cancer, Normobaric hyperoxia, Paclitaxel, Chemoresistance
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|